MDxHealth SA

NasdaqCM MDXH

MDxHealth SA Return on Assets (ROA) for the year ending December 31, 2023: -33.38%

MDxHealth SA Return on Assets (ROA) is -33.38% for the year ending December 31, 2023, a 20.77% change year over year. Return on assets measures profitability against assets; higher ROA indicates efficient asset use and profitability.

MDxHealth SA Return on Assets (ROA) for the year ending December 31, 2022 was -42.13%, a -2.42% change year over year.
MDxHealth SA Return on Assets (ROA) for the year ending December 31, 2021 was -41.13%, a 56.34% change year over year.
MDxHealth SA Return on Assets (ROA) for the year ending December 31, 2020 was -94.20%, a 11.21% change year over year.
MDxHealth SA Return on Assets (ROA) for the year ending December 31, 2019 was -106.08%, a -114.05% change year over year.

Key data

Date	Return on Assets (ROA)	Return on Equity (ROE)	Return on Capital Employed (ROCE)	Interest Coverage Ratio

NasdaqCM: MDXH

MDxHealth SA

CEO	Mr. Michael K. McGarrity
IPO Date	Nov. 4, 2021
Location	Belgium
Headquarters	CAP Business Center
Employees	300
Sector	Health Care
Industries Pharmaceuticals Clinical Trials Medical Instruments

Description

MDxHealth SA, a commercial-stage precision diagnostics company, provides urologic solutions in the United States, the Netherlands, Belgium, Spain, Poland, Italy, rest of European Union, and internationally. Its novel prostate cancer genomic testing solutions are SelectMDx, a non-invasive urine test; and ConfirmMDx, an epigenetic test, which provide physicians with a clinical pathway to identify clinically prostate cancer while minimizing the use of invasive procedures that are prone to complications. The company was formerly known as OncoMethylome Sciences SA and changed its name to MDxHealth SA in October 2010. MDxHealth SA was incorporated in 2003 and is headquartered in Herstal, Belgium.

Key trends

Past 5 years